Brief: Theriva Biologics Announces Progress In Virage
02/08/2023 12:14
Aug 2 (Reuters) - Theriva Biologics Inc TOVX.A :
* THERIVA™ BIOLOGICS ANNOUNCES KEY PROGRESS IN VIRAGE, AN
ONGOING,
MULTINATIONAL PHASE 2B TRIAL OF VCN-01 IN COMBINATION WITH
CHEMOTHERAPY IN PANCREATIC DUCTAL ADENOCARCINOMA
* THERIVA BIOLOGICS INC - INITIATED DOSING AT U.S. SITES FOR
VIRAGE
* THERIVA BIOLOGICS INC - SECOND DOSES OF INTRAVENOUS
VCN-01ADMINISTERED TO PATIENTS IN SPAIN AND WERE WELL TOLERATED
* THERIVA BIOLOGICS INC - VIRAGE REMAINS ON TRACK TO
COMPLETE
ENROLLMENT IN Q1 OF 2024
Source text for Eikon: ID:nGNXk4j68
Further company coverage: TOVX.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theriva Biologics
See all newsTheriva Biologics Q2 net loss narrows on lower R&D costs, expenses
Brief: Theriva™ Biologics Announces Upcoming Presentation Of Additional Data From The Virage Phase 2B Clinical Trial Of Vcn-01 In Metastatic Pancreatic Cancer At Aacr 2026 Annual Meeting
Brief: Theriva Biologics Licenses Syn-020 To Rasayana Therapeutics For Multiple Indications
Brief: Theriva Biologics Implements 32% Workforce Reduction - SEC Filing
Brief: Theriva™ Biologics Announces Presentation Of Data From Vcn-01 Retinoblastoma Phase 1 Clinical Trial At Asco 2025